249 related articles for article (PubMed ID: 29908352)
21. ALG13-Congenital Disorder of Glycosylation (ALG13-CDG): Updated clinical and molecular review and clinical management guidelines.
Shah R; Eklund EA; Radenkovic S; Sadek M; Shammas I; Verberkmoes S; Ng BG; Freeze HH; Edmondson AC; He M; Kozicz T; Altassan R; Morava E
Mol Genet Metab; 2024 Jun; 142(2):108472. PubMed ID: 38703411
[TBL] [Abstract][Full Text] [Related]
22. Further delineation of COG8-CDG: A case with novel compound heterozygous mutations diagnosed by targeted exome sequencing.
Yang A; Cho SY; Jang JH; Kim J; Kim SZ; Lee BH; Yoo HW; Jin DK
Clin Chim Acta; 2017 Aug; 471():191-195. PubMed ID: 28619360
[TBL] [Abstract][Full Text] [Related]
23. Dolichol kinase deficiency (DOLK-CDG) with a purely neurological presentation caused by a novel mutation.
Helander A; Stödberg T; Jaeken J; Matthijs G; Eriksson M; Eggertsen G
Mol Genet Metab; 2013 Nov; 110(3):342-4. PubMed ID: 23890587
[TBL] [Abstract][Full Text] [Related]
24. Congenital disorders of glycosylation.
Jaeken J
Ann N Y Acad Sci; 2010 Dec; 1214():190-8. PubMed ID: 21175687
[TBL] [Abstract][Full Text] [Related]
25. DDOST-CDG: Clinical and molecular characterization of a third patient with a milder and a predominantly movement disorder phenotype.
Elsharkawi I; Wongkittichote P; Daniel EJP; Starosta RT; Ueda K; Ng BG; Freeze HH; He M; Shinawi M
J Inherit Metab Dis; 2023 Jan; 46(1):92-100. PubMed ID: 36214423
[TBL] [Abstract][Full Text] [Related]
26. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
[TBL] [Abstract][Full Text] [Related]
27. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing.
Timal S; Hoischen A; Lehle L; Adamowicz M; Huijben K; Sykut-Cegielska J; Paprocka J; Jamroz E; van Spronsen FJ; Körner C; Gilissen C; Rodenburg RJ; Eidhof I; Van den Heuvel L; Thiel C; Wevers RA; Morava E; Veltman J; Lefeber DJ
Hum Mol Genet; 2012 Oct; 21(19):4151-61. PubMed ID: 22492991
[TBL] [Abstract][Full Text] [Related]
28. SLC35A2-CDG: novel variants with two ends of the spectrum.
Kasapkara ÇS; Ceylan AC; Özyürek H; Karakaya Molla G; Civelek Ürey B; Kıreker Köylü O; Küçükçongar Yavaş A; Sönmez FM
J Pediatr Endocrinol Metab; 2021 Sep; 34(9):1185-1189. PubMed ID: 34161696
[TBL] [Abstract][Full Text] [Related]
29. The second DDOST-CDG patient with lactose intolerance, developmental delay, and situs inversus totalis.
Pi S; Gong J; Xiao W; Xiao B; Mao X; Long H
J Hum Genet; 2022 Feb; 67(2):103-106. PubMed ID: 34462534
[TBL] [Abstract][Full Text] [Related]
30. Is MED13L-related intellectual disability a recognizable syndrome?
Tørring PM; Larsen MJ; Brasch-Andersen C; Krogh LN; Kibæk M; Laulund L; Illum N; Dunkhase-Heinl U; Wiesener A; Popp B; Marangi G; Hjortshøj TD; Ek J; Vogel I; Becher N; Roos L; Zollino M; Fagerberg CR
Eur J Med Genet; 2019 Feb; 62(2):129-136. PubMed ID: 29959045
[TBL] [Abstract][Full Text] [Related]
31. Molecular diagnostic testing for congenital disorders of glycosylation (CDG): detection rate for single gene testing and next generation sequencing panel testing.
Jones MA; Rhodenizer D; da Silva C; Huff IJ; Keong L; Bean LJ; Coffee B; Collins C; Tanner AK; He M; Hegde MR
Mol Genet Metab; 2013; 110(1-2):78-85. PubMed ID: 23806237
[TBL] [Abstract][Full Text] [Related]
32. Use of Endoglycosidase H as a diagnostic tool for MAN1B1-CDG patients.
Duvet S; Mouajjah D; Péanne R; Matthijs G; Raymond K; Jaeken J; Morava E; Foulquier F
Electrophoresis; 2018 Dec; 39(24):3133-3141. PubMed ID: 29947113
[TBL] [Abstract][Full Text] [Related]
33. Congenital Disorders of Glycosylation in Portugal-Two Decades of Experience.
Quelhas D; Martins E; Azevedo L; Bandeira A; Diogo L; Garcia P; Sequeira S; Ferreira AC; Teles EL; Rodrigues E; Fortuna AM; Mendonça C; Fernandes HC; Medeira A; Gaspar A; Janeiro P; Oliveira A; Laranjeira F; Ribeiro I; Souche E; Race V; Keldermans L; Matthijs G; Jaeken J
J Pediatr; 2021 Apr; 231():148-156. PubMed ID: 33340551
[TBL] [Abstract][Full Text] [Related]
34. Congenital disorder of glycosylation type Id (CDG Id): phenotypic, biochemical and molecular characterization of a new patient.
Rimella-Le-Huu A; Henry H; Kern I; Hanquinet S; Roulet-Perez E; Newman CJ; Superti-Furga A; Bonafé L; Ballhausen D
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S381-6. PubMed ID: 18679822
[TBL] [Abstract][Full Text] [Related]
35. Disorder of sex development associated with a novel homozygous nonsense mutation in COG6 expands the phenotypic spectrum of COG6-CDG.
Lugli L; Bariola MC; Ferri L; Lucaccioni L; Bertucci E; Cattini U; Torcetta F; Morrone A; Iughetti L; Berardi A
Am J Med Genet A; 2021 Apr; 185(4):1187-1194. PubMed ID: 33394555
[TBL] [Abstract][Full Text] [Related]
36. High-resolution mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation.
van Scherpenzeel M; Steenbergen G; Morava E; Wevers RA; Lefeber DJ
Transl Res; 2015 Dec; 166(6):639-649.e1. PubMed ID: 26307094
[TBL] [Abstract][Full Text] [Related]
37. ALG13-CDG in a male with seizures, normal cognitive development, and normal transferrin isoelectric focusing.
Gadomski TE; Bolton M; Alfadhel M; Dvorak C; Ogunsakin OA; Nelson SL; Morava E
Am J Med Genet A; 2017 Oct; 173(10):2772-2775. PubMed ID: 28777499
[TBL] [Abstract][Full Text] [Related]
38. SLC35A2-related congenital disorder of glycosylation: Defining the phenotype.
Yates TM; Suri M; Desurkar A; Lesca G; Wallgren-Pettersson C; Hammer TB; Raghavan A; Poulat AL; Møller RS; Thuresson AC; Balasubramanian M
Eur J Paediatr Neurol; 2018 Nov; 22(6):1095-1102. PubMed ID: 30194038
[TBL] [Abstract][Full Text] [Related]
39. Ten years of screening for congenital disorders of glycosylation in Argentina: case studies and pitfalls.
Asteggiano CG; Papazoglu M; Bistué Millón MB; Peralta MF; Azar NB; Spécola NS; Guelbert N; Suldrup NS; Pereyra M; Dodelson de Kremer R
Pediatr Res; 2018 Dec; 84(6):837-841. PubMed ID: 30397276
[TBL] [Abstract][Full Text] [Related]
40. Adult phenotype and further phenotypic variability in SRD5A3-CDG.
Kara B; Ayhan Ö; Gökçay G; Başboğaoğlu N; Tolun A
BMC Med Genet; 2014 Jan; 15():10. PubMed ID: 24433453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
